Engineering immune cell therapies for inflammatory bowel disease: from stem cells to CAR T cells.

CD19-targeted CAR T cell therapy can induce long-term remission of intestinal inflammation in ulcerative colitis, revealing a key role for mucosal B cells and plasmablasts.

• Why it matters: Effective treatment options for inflammatory bowel disease (IBD) remain limited despite advances in small molecules and antibody therapies, highlighting the need for innovative approaches. Understanding the pathogenic role of immune cells like B cells and plasmablasts in IBD could open new therapeutic avenues.
• What they did: The authors review emerging cellular immunotherapies, including stem cell-based treatments, regulatory T cell therapies, and CAR T cell platforms, with early clinical trials exploring their safety and efficacy.
• The result: The case report suggests CAR T cell strategies may offer transformative potential for IBD treatment, but rigorous clinical trials are necessary to confirm their safety and therapeutic benefit.